Developing a Hybrid CMV Vaccine

Developing a hybrid CMV Vaccine Cytomegalovirus (CMV), upon entering the cell, releases a highly evolved protein arsenal to disrupt cellular defenses. One strategy to defeat the virus in humans may be to use a murine version of the pathogen, MCMV. Interspecies infections are inefficient because the mouse virus is attuned to infecting mice and is blocked in humans at several steps in its life cycle, especially at PML bodies in the nucleus. By adding certain human genes, researchers may be

Written byAlan Dove
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Cytomegalovirus (CMV), upon entering the cell, releases a highly evolved protein arsenal to disrupt cellular defenses. One strategy to defeat the virus in humans may be to use a murine version of the pathogen, MCMV. Interspecies infections are inefficient because the mouse virus is attuned to infecting mice and is blocked in humans at several steps in its life cycle, especially at PML bodies in the nucleus. By adding certain human genes, researchers may be able to create a hybrid virus that overcomes these blocks and produces enough infection to elicit long lasting immunity.

Please download the Adobe Flash Player to view this content:

In the battle between host and viral proteins, viral pp71 suppresses Daxx activity, and the splicing variant of the immediate early gene, IE1 represses Daxx and HDACs. IE1 and IE2 facilitate expression of the early protein 112/113. 112/113 blocks some of the activity of the IE2 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies